Breaking News, Collaborations & Alliances

Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product

ANDA holder Sagent will sell, market and distribute the drug product in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) headquartered in Hunt Valley, MD, will manufacture commercial supply of Fulvestrant Injection 250mg/5ml drug product, which was recently approved by the FDA. Pii will be responsible for all commercial drug product production and Sagent Pharmaceuticals, the ANDA holder, will sell, market and distribute the drug product in the U.S.   “We are pleased to support Sagent Pharmaceuticals in its e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters